Harvard Bioscience, Inc.

HBIO Healthcare Medical Instruments & Supplies

Harvard Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $86.6 million, down 8.06% from fiscal 2024.

Revenue
+11.1%
EPS
−28.0%
Free cash flow
−123.4%
Total debt
+5.21%

Quarter to June 2026, against a year earlier

8.55 0.06 −0.70%
Market cap
$38.5M
P/E
0.0×
Fwd P/E
−4.6×
Dividend yield
—
F-score
4/9
Altman Z
−4.01
Beneish M
−6.52
Dividend safety
n/a

Harvard Bioscience, Inc. (HBIO) P/E ratio

Alert me on P/E ratio

Harvard Bioscience, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 826× (March 2015) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
42 more quarters

Against its own ten years

Low 0.0× High 826×
Ten-year median 0.0×
Current reading's percentile 98

P/E ratio against peers

Company P/E ratio
POCI Precision Optics Corp. compare n/m
MLSS Milestone Scientific, Inc. compare n/m
HBIO Harvard Bioscience, Inc. n/m
BNGO Bionano Genomics, Inc. compare n/m
RVP Retractable Technologies, Inc. compare n/m
ZTEKF Zentek Ltd. compare n/m
DXR Daxor Corporation compare 4.0×
NEPH Nephros Inc. compare 18.0×
DAVI Davion Healthcare PLC compare —
Medical Instruments & Supplies industry median 30.3×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on HBIO